105990-27-0

Basic information

• Product Name: (S)-(-)-HigenaMine HydrobroMide
• Synonyms: (S)-(-)-HigenaMine HydrobroMide;(1S)-1,2,3,4-Tetrahydro-1-[(4-hydroxyphenyl)methyl]-6,7-isoquinolinediol hydrobromide (1:1);(S)-(-)-Norcoclaurine hydrobromide;(-)-Higenamine hydrobromide;(1S)-1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol:hydrobromide
• CAS NO: 105990-27-0
• Molecular Formula: C16H18BrNO3
• Molecular Weight: 352.22302
• Product Categories: Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 105990-27-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: (S)-(-)-HigenaMine HydrobroMide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(-)-HigenaMine HydrobroMide(105990-27-0)
• EPA Substance Registry System: (S)-(-)-HigenaMine HydrobroMide(105990-27-0)

Safety Data

• Hazardous Substances Data: 105990-27-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-(-)-HigenaMine HydrobroMide is used as an intermediate compound for the synthesis of (-)-Higenamine (H325800), a naturally occurring alkaloid with potential applications in the development of new drugs and therapies. Its role in the synthesis process is crucial, as it serves as a building block for creating the final product, (-)-Higenamine, which may have various pharmacological properties and uses.

Relevant articles and documents

Enantioselective synthesis of (R)-(+)- and (S)-(-)-higenamine and their analogues with effects on platelet aggregation and experimental animal model of disseminated intravascular coagulation

Optically active tetrahydroisoquinoline alkaloids, (R)-(+)-higenamine (1R) and (S)-(-)-higenamine (1 S), and their optically active 1-naphthylmethyl analogues (2 and 3), were synthesized by enantioselective hydrogenation of the corresponding dihydroisoqui

NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS

The disclosure concerns novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions. The enantiomers of tetrahydroisoquinoline derivatives are provided which are useful in stimulating heart rate and hypotensive activity, inhibitory activity against platelet aggregation, and suppressive against inducible NO synthase. The enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts are effective for treating congestive heart failure, hypertension, thrombosis, inflammation, septicemia, cardiac insufficiency, and disseminated intravascular coagulopathy.